Clinical trials: Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4)
Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4)
Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)
The purpose of this study is to evaluate the safety and tolerability of multiple doses of ND-L02-s0201 in subjects with moderate to extensive hepatic fibrosis.
- Trial name
- NCT02227459
- Testing
- ND-L02-s0201 Injection
- Where
- 2 sites in United States, Bulgaria
- Volunteers
- 25 people
- Sponsor
- Bristol-Myers Squibb